ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 255 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,312 | -58.3% | 197,723 | -44.6% | 0.00% | -62.5% |
| Q2 2023 | $12,726 | +58.6% | 356,881 | +12.9% | 0.01% | +100.0% |
| Q1 2023 | $8,026 | -41.7% | 315,982 | -6.8% | 0.00% | -33.3% |
| Q4 2022 | $13,757 | -99.9% | 339,181 | +13.7% | 0.01% | -45.5% |
| Q3 2022 | $9,859,000 | +17.8% | 298,297 | +25.5% | 0.01% | +120.0% |
| Q2 2022 | $8,372,000 | +24.8% | 237,760 | +63.0% | 0.01% | 0.0% |
| Q1 2022 | $6,710,000 | -81.1% | 145,909 | -72.7% | 0.01% | -28.6% |
| Q4 2021 | $35,448,000 | +161.2% | 534,644 | +145.9% | 0.01% | +16.7% |
| Q3 2021 | $13,571,000 | -20.9% | 217,384 | +5.0% | 0.01% | -25.0% |
| Q2 2021 | $17,148,000 | +15.2% | 207,069 | -7.7% | 0.01% | 0.0% |
| Q1 2021 | $14,883,000 | +18.0% | 224,435 | +36.5% | 0.01% | +14.3% |
| Q4 2020 | $12,615,000 | +47.2% | 164,396 | -17.4% | 0.01% | +40.0% |
| Q3 2020 | $8,568,000 | +1.5% | 198,963 | +1.8% | 0.01% | -28.6% |
| Q2 2020 | $8,445,000 | +57.8% | 195,522 | +5.1% | 0.01% | +75.0% |
| Q1 2020 | $5,351,000 | -40.9% | 185,948 | +30.2% | 0.00% | -20.0% |
| Q4 2019 | $9,058,000 | +190.7% | 142,813 | +29.2% | 0.01% | +150.0% |
| Q3 2019 | $3,116,000 | -0.5% | 110,547 | -6.4% | 0.00% | 0.0% |
| Q2 2019 | $3,131,000 | +145.2% | 118,130 | +69.9% | 0.00% | +100.0% |
| Q1 2019 | $1,277,000 | +734.6% | 69,534 | +462.3% | 0.00% | – |
| Q4 2018 | $153,000 | -85.6% | 12,365 | -77.7% | 0.00% | -100.0% |
| Q3 2018 | $1,062,000 | +21.6% | 55,350 | -13.7% | 0.00% | 0.0% |
| Q2 2018 | $873,000 | -6.9% | 64,152 | -50.7% | 0.00% | 0.0% |
| Q1 2018 | $938,000 | +67.8% | 130,172 | -14.2% | 0.00% | – |
| Q4 2017 | $559,000 | +117.5% | 151,773 | +155.2% | 0.00% | – |
| Q3 2017 | $257,000 | +3.2% | 59,465 | -61.5% | 0.00% | – |
| Q2 2017 | $249,000 | +79.1% | 154,298 | +106.6% | 0.00% | – |
| Q1 2017 | $139,000 | +124.2% | 74,692 | +83.0% | 0.00% | – |
| Q4 2016 | $62,000 | -78.8% | 40,805 | +2.6% | 0.00% | – |
| Q3 2016 | $293,000 | +202.1% | 39,772 | +114.3% | 0.00% | – |
| Q2 2016 | $97,000 | – | 18,560 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,264 | $54,392,000 | 33.22% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $216,228,000 | 28.00% |
| L1 Capital Pty Ltd | 296,024 | $19,629,000 | 4.93% |
| Aquilo Capital Management, LLC | 407,926 | $27,050,000 | 4.89% |
| Evolutionary Tree Capital Management, LLC | 72,948 | $4,837,000 | 2.86% |
| ACUTA CAPITAL PARTNERS, LLC | 108,000 | $7,161,000 | 2.58% |
| First Light Asset Management, LLC | 536,836 | $35,598,000 | 2.36% |
| Parkman Healthcare Partners LLC | 70,089 | $4,648,000 | 1.08% |
| Hood River Capital Management LLC | 357,082 | $23,678,000 | 0.76% |
| Vanguard Capital Wealth Advisors | 11,099 | $703,565,000 | 0.60% |